Cantor Fitzgerald raises Eli Lilly stock price target on guidance

Cantor Fitzgerald raised its price target on Eli Lilly to $1,230 from $1,205 while keeping an Overweight rating, citing strong Mounjaro adoption outside the U.S. and encouraging early uptake for the oral obesity drug launch. The firm lifted its 2026 EPS estimate to $37.50, above company guidance of $35.50-$37.00, after Lilly raised fiscal 2026 revenue guidance by $2 billion to $82 billion-$85 billion. The article also notes Q1 2026 EPS of $8.55 versus $6.97 expected and revenue of $19.8 billion versus $17.6 billion consensus, underscoring strong operating momentum.

Analysis

The important takeaway is not the size of the guidance bump, but the operating leverage embedded in the new framework. When a company can convert incremental revenue into disproportionate EPS upside, the market usually underestimates how quickly consensus can ratchet higher over the next 1-2 quarters, especially if channel checks keep confirming demand is supply-constrained rather than promotional-led. That creates a favorable setup for multiple expansion even if the absolute revenue beat rate normalizes.

Competitive dynamics are more nuanced than a simple winner-take-all GLP-1 trade. A steadier oral launch reduces the odds of a near-term share-shift shock that would have forced rivals into aggressive pricing or heavier DTC spending; that is modestly constructive for NVO in the short run because it lowers the probability of a sudden margin war. But if the oral ramp keeps building into the third quarter, the real pressure shifts to formulary access, prescriber conversion, and class-wide patient persistence, which can stretch the leader’s advantage and force competitors to defend share with rebates rather than volume.

The contrarian risk is that the market may be extrapolating too much from early prescription data and from a guidance raise that may already reflect conservative assumptions. If launch cadence underwhelms into late summer, the stock can de-rate quickly because the current valuation embeds a cleaner second-half inflection than the evidence may yet justify. The key catalyst window is the next 6-10 weeks: if promotional activity and refill behavior confirm acceleration, estimates can keep moving up; if not, the trade becomes a valuation-and-expectations miss rather than a fundamental story break.

For portfolio construction, the cleaner expression is to own the leader against the most direct valuation peers only if you can tolerate event risk around launch data and broader semaglutide-class read-throughs. The better asymmetry may come from using options to capture upside while limiting downside if the market decides the early oral rollout is merely adequate rather than exceptional. In that scenario, the stock likely still grinds higher on fundamentals, but not fast enough to justify chasing spot after a large rerating.

Key Decisions for Investors

• Maintain a tactical long LLY position into the next 6-10 weeks; upside remains tied to continued estimate revisions, with downside limited unless launch momentum clearly stalls.
• Buy LLY call spreads 3-6 months out rather than stock outright to express upside from second-half acceleration while capping risk if oral uptake proves merely adequate.
• Pair long LLY vs short NVO only on weakness, not strength; the trade works best if U.S. leader execution keeps widening the growth gap and forcing competitive rebate pressure over the next 2-3 quarters.
• If you already own LLY, consider trimming into strength after sharp post-earnings moves and reloading on any 5-8% pullback tied to concerns about oral launch pacing.
• Avoid shorting LLY into this setup unless you have evidence of prescription deceleration; the near-term path of least resistance remains upward as long as guidance remains conservative relative to demand.